Regulon is an oncology-focused drug delivery company leveraging proprietary and differentiated tumor-targeting nanotechnology to develop improved branded versions of leading chemotherapy drugs.
Our lead product, Lipoplatin for pancreatic cancer (same drug under the name Nanoplatin for non-small cell lung cancer, NSCLC), is a liposomally encapsulated cisplatin nanoparticle. Cisplatin is the most widely-used chemotherapy drug, the gold standard for epithelial malignancies with applications to over 50% of human cancers.
Lipoplatin nanoparticles, loaded with cisplatin are uptaken by tumors and metastases (10 to 200-fold higher than normal tissue) by leaking through the compromised endothelium of tumor vasculature sprouted during neoangiogenesis, a process known as extravasation, and by the avidity of tumors for nutrients with Lipoplatin disguised as a nutrient with its lipid shell. Moreover, Lipoplatin nanoparticles fuse with the cell membrane thus emptying their toxic payload directly inside the cytoplasm of the cell bypassing the cell membrane barrier often impermeable by cisplatin especially in resistant tumors.
Thus, the significant advantages of this formulation are:
Additional emerging properties unique to Lipoplatin are:
Published Phase III studies show a lower toxicity with improved therapeutic index in adenocarcinomas of the lungs compared to cisplatin; this feature was not shown by other platinum blockbuster drugs (carboplatin, oxaliplatin). In a randomized Phase III in NSCLC, a statistically significant reduction of neutropenia, nephrotoxicity and asthenia of cisplatin was demonstrated by its replacement with Lipoplatin. Also in a randomized Phase III in nonsquamous-NSCLC the partial response for the Lipoplatin arm was 59% compared to 42% for the cisplatin arm and the difference was statistically significant (p=0.036).
Apollonos 1 - Industrial Zone Koropi 19400 - Athens Greece
Tel: +30 210 6628 284 // email: firstname.lastname@example.org